Top in cardiology: Chest pain guidelines, telecardiology advances
The American Heart Association, American College of Cardiology and five other societies established new guidelines for chest pain, with focuses on informing patients, listening to women and coronary artery calcium testing.
A review of the inaugural guidelines was the top story in cardiology last week.

The second top story explored how telecardiology necessitated by the COVID-19 pandemic has improved the quality of and disparities in patient care. While some routine care may continue to be delivered virtually, there are issues that need to be addressed.
Read these and more top stories in cardiology below:
Inaugural chest pain guideline offers ‘standard approach to evaluating patients’
The American Heart Association and American College of Cardiology recently released the first chest pain guideline written under their purview. Read more.
Telecardiology advances rapidly in COVID-19 era
The COVID-19 pandemic continues to challenge our health care system to deliver essential inpatient and outpatient care to infected patients while continuing to treat patients with non-COVID-19-related illnesses. Read more.
COVID-19 diagnosis in patients with STEMI tied to elevated in-hospital mortality
In a cohort of patients with STEMI, a COVID-19 diagnosis significantly increased the rates of in-hospital mortality compared with patients without a COVID-19 diagnosis from the past year, according to new data. Read more.
Early surgery shows benefit vs watchful waiting for asymptomatic severe aortic stenosis
In the AVATAR trial, patients with asymptomatic severe aortic stenosis and normal left ventricular function assigned early surgical aortic valvular replacement, compared with watchful waiting, had a lower incidence of death and cardiovascular outcomes. Read more.
FDA grants priority review of empagliflozin for adults with HF, regardless of LVEF
The FDA has accepted a supplemental new drug application and granted priority review of empagliflozin for the reduction of cardiovascular death and heart failure hospitalization for adults with heart failure, regardless of left ventricular ejection fraction. Read more.